The role of molecular genetic testing in modern breast health management

South African Family Practice

Volumn 47, Issue 9, 2005, Pages 38-40

  Kotze, M J ^a,e   Malan, J ^b   Pienaar, R ^c   Apffelstaedt, J ^d  

^a Christiaan Barnard Memorial Hospital   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

^c GVI Oncology   (South Africa)

^d Apffelstaedt and Associates   (South Africa)

^e NONE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; DIAGNOSTIC TEST; ENVIRONMENTAL FACTOR; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HEALTH CARE MANAGEMENT; HEREDITY; HUMAN; LIFESTYLE; MOLECULAR GENETICS; NEUROTOXICITY; REVIEW; RISK FACTOR; RISK REDUCTION; SOUTH AFRICA; TUMOR SUPPRESSOR GENE;

EID: 29644437683     PISSN: 20786190     EISSN: 20786204     Source Type: Journal    
DOI: 10.1080/20786204.2005.10873286     Document Type: Review

References (15)

1. Althuis MD, Dozier JM, Anderson WF, et al. Global trends in breast cancer incidence and mortality 1973-1997. Int J Nat Cancer Ins 2005; Published online.
2. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: An epidemiological review. J Natl Cancer Inst 2000; 92: 874-897.
3. th Biennial Congress of the Southern African Society of Human Genetics. Durban, South Africa, May 2003.
4. Reeves MD, Yawitch TM, van der Merwe NC, et al. BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families. Int J Cancer 2004; 110: 677-682.
5. th Biennial Congress of the Southern African Society of Human Genetics. Muldersdrift, South Africa, March 2005.
6. King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
7. Donaldson MS. Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutr J 2004; 3: 19 (www.nutritionj.com/content/3/1/19).
8. Kotze MJ, Badenhorst H. Chronic disease risk management: Combining genetic testing with medical and nutrition therapy. SA Fam Pract 2005; 47 (4): 40-42.
9. Mitrunen K, Kataja V, Eskelinen M, et al. Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics 2002; 12: 67-72.
10. Cheng TC, Chen ST, Huang CS, et al. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: A multigenic study on cancer susceptibility. Int J Cancer 2005; 113: 345-353.
11. Kocabas NA, Sardas S, Cholerton S, et al. Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. Cell Biochem Funct 2005; 23: 73-76.
12. Goodman JE, Lavigne JA, Wu K, et al. COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 2001; 22: 1661-1665.
13. Haase D, Binder C, Bunger J, et al. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 2002; 26: 249-254.
14. Van Kuilenburg ABP, De Abreu RA, Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40: 41-45.
15. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002; 347: 1999-2009.